Astellas Announces Topline Results from Phase 3 Long-Term Safety Study of Fezolinetant in Mainland China
/PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., "Astellas") today announced topline results from the Phase 3...
Kenji Yasukawa Ahsan Arozullah Przegl Menopauzalny Astellas Pharma Inc Head Of Development Therapeutic Areas Prnewswire Astellas Pharma Inc
Source: prnewswire.com